%0 Journal Article
%A Kampers, Linde F C
%A Metselaar, Dennis
%A Vinci, Maria
%A Scirocchi, Fabio
%A Veldhuijzen van Zanten, Sophie
%A Eyrich, Matthias
%A Biassoni, Veronica
%A Hulleman, Esther
%A Karremann, Michael
%A Stücker, Wilfried
%A Van Gool, Stefaan W
%T The Complexity of Malignant Glioma Treatment.
%J Cancers
%V 17
%N 5
%@ 2072-6694
%C Basel
%I MDPI
%M DKFZ-2025-00538
%P 879
%D 2025
%X Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.
%K immunotherapy (Other)
%K malignant glioma (Other)
%K tumor microenvironment (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40075726
%R 10.3390/cancers17050879
%U https://inrepo02.dkfz.de/record/299783